Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.05 CAD | -2.38% | -0.49% | -24.07% |
04-17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
04-17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
William Radvak
FOU | Founder | 61 | 18/01/17 |
Michael Kelly
CEO | Chief Executive Officer | 59 | 09/04/23 |
Bill Adams
DFI | Director of Finance/CFO | 62 | 23/02/20 |
Daniel Mikol
CTO | Chief Tech/Sci/R&D Officer | - | 04/05/21 |
Adam Rogers
BRD | Director/Board Member | - | 13/07/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Randall Kaye
BRD | Director/Board Member | 62 | 27/10/20 |
Brian Bayley
BRD | Director/Board Member | 71 | 15/05/18 |
William Radvak
FOU | Founder | 61 | 18/01/17 |
Michael Kelly
CEO | Chief Executive Officer | 59 | 09/04/23 |
Harold Punnett
FOU | Founder | 67 | 18/01/17 |
John Thompson
BRD | Director/Board Member | 57 | 12/04/22 |
John Ruffolo
BRD | Director/Board Member | - | 16/10/23 |
Glenn Ives
BRD | Director/Board Member | 62 | 31/08/21 |
Adam Rogers
BRD | Director/Board Member | - | 13/07/22 |
Director/Board Member | - | 31/08/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 69,927,649 | 53,893,753 ( 77.07 %) | 0 | 77.07 % |
Company contact information
NervGen Pharma Corp.
112-970 Burrard Street Unit 1290
V6Z 2R4, Vancouver
+778-731-1711
http://www.nervgen.comSector
Sales per region
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-24.07% | 104M | |
+0.67% | 42.4B | |
+47.02% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- NGEN Stock
- Company NervGen Pharma Corp.